Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer (Q81351655)
Jump to navigation
Jump to search
scientific article published on 01 June 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer |
scientific article published on 01 June 2008 |
Statements
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer (English)
Catherine Lhommé
Florence Joly
Joan L Walker
Andrea A Lissoni
Maria O Nicoletto
Gregory M Manikhas
Mark M O Baekelandt
Alan N Gordon
Paula M Fracasso
William L Mietlowski
Gary J Jones
Margaret H Dugan